

University of Groningen

Evaluation of hemostasis in patients with end-stage renal disease

Gäckler, Anja; Rohn, Hana; Lisman, Ton; Benkö, Tamas; Witzke, Oliver; Kribben, Andreas; Saner, Fuat H

Published in:
 PLoS ONE

DOI:
[10.1371/journal.pone.0212237](https://doi.org/10.1371/journal.pone.0212237)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
 Publisher's PDF, also known as Version of record

Publication date:
 2019

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Gäckler, A., Rohn, H., Lisman, T., Benkö, T., Witzke, O., Kribben, A., & Saner, F. H. (2019). Evaluation of hemostasis in patients with end-stage renal disease. *PLoS ONE*, 14(2), [e0212237].
<https://doi.org/10.1371/journal.pone.0212237>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

RESEARCH ARTICLE

Evaluation of hemostasis in patients with end-stage renal disease

Anja Gäckler^{1*}, Hana Rohn², Ton Lisman³, Tamas Benkő⁴, Oliver Witzke², Andreas Kribben¹, Fuat H. Saner⁴

1 Department of Nephrology, University Hospital Essen, University Duisburg-Essen, Essen, Germany, **2** Department of Infectious Diseases, University Hospital Essen, University Duisburg-Essen, Essen, Germany, **3** Surgical Research Laboratory and Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University of Groningen University Medical Center Groningen, Groningen, The Netherlands, **4** Department of General, Visceral and Transplant Surgery, University Hospital Essen, University Duisburg-Essen, Essen, Germany

* anja.gaeckler@uk-essen.de



OPEN ACCESS

Citation: Gäckler A, Rohn H, Lisman T, Benkő T, Witzke O, Kribben A, et al. (2019) Evaluation of hemostasis in patients with end-stage renal disease. PLoS ONE 14(2): e0212237. <https://doi.org/10.1371/journal.pone.0212237>

Editor: Pablo Garcia de Frutos, Institut d'Investigacions Biomediques de Barcelona, SPAIN

Received: November 26, 2018

Accepted: January 29, 2019

Published: February 20, 2019

Copyright: © 2019 Gäckler et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its Supporting Information files.

Funding: The authors received no specific funding for this work.

Competing interests: The authors of this manuscript have read the journal's policy and have the following competing interests: AG reports personal fees from Alexion and Ablynx/Sanofi. AK reports grants and personal fees from Alexion. OW reports grants and personal fees from Alexion and Pfizer. HR, TL and TB declare no conflicts of

Abstract

An increased bleeding risk is reported for patients with end-stage renal disease. This study aims to analyze, whether bleeding risk can be assessed by global tests of hemostasis. Standard laboratory tests and an extended evaluation of hemostasis by rotational thromboelastometry, platelet function analyzer (PFA) and multiple electrode aggregometry as well as thrombin generation assays and measurement of fibrinolytic potential were performed in 20 patients on hemodialysis, 10 patients on peritoneal dialysis, 10 patients with chronic kidney disease stage G5 (CKD5) and in 10 healthy controls (HC). Hemoglobin was significantly lower in patients with end-stage renal disease versus HC (each $p < 0.01$). Patients on peritoneal dialysis showed increased fibrinogen levels compared to HC ($p < 0.01$), which were also reflected by FIBTEM results (each $p < 0.05$). 41% of hemodialysis patients and 44% of CKD5 patients presented with prolonged PFA-ADP-test ($p < 0.05$), while no patient on peritoneal dialysis and no HC offered this modification. Thrombin generating potential was significantly lower in patients on hemodialysis, while clot lysis time revealed a hypofibrinolytic state in patients on hemo- and peritoneal dialysis compared to HC ($p < 0.001$). In conclusion, patients with end-stage renal disease have complex hemostatic changes with both hyper- and hypocoagulable features, which are dependent on use and type of dialysis. Hypercoagulable features include elevated fibrinogen levels and a hypofibrinolytic state, whereas hypocoagulable features include decreased thrombin generating capacity and platelet dysfunction. Our results may contribute to a more rational approach to hemostatic management in these patients.

Introduction

An increased bleeding risk has been described for patients with end-stage renal disease. Bleeding occurs in about 50% of patients with end-stage renal disease [1, 2] reaching from minor events such as bruises and bleeding at venipuncture sites to menorrhagia, gastrointestinal

interest. FHS reports personal fees from CSL Behring, TEM International and Biotest. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

blood loss, severe perioperative bleeding and retroperitoneal as well as intracranial hemorrhage. Bleeding can significantly contribute to mortality and morbidity and blood transfusions can lead to alloimmunization and thereby limit options for transplantation [3].

Bleeding diathesis is multifactorial and attributed to morphological changes of the vessels, anaemia, thrombocytopenia and uraemic disturbance of platelet adhesion and aggregation, coagulation and fibrinolysis [2, 4, 5].

Although predisposition to bleeding seems obvious, recommendations for risk determination are missing as no single factor or test has been established to detect individual bleeding risk in patients with end-stage renal disease.

On the other hand, the risk of venous thromboembolism is also increased in patients with end-stage renal disease [6, 7], making risk management even more challenging.

In addition, patients with end-stage renal disease do not represent a homogenous cohort as they include patients with pharmaceutical treatment only, patients with hemodialysis and patients with peritoneal dialysis. Comparative data including less frequently used tests such as rotational thromboelastometry, multiple electrode aggregometry, thrombin generation assays and test of fibrinolytic potential for determination and characterization of plasmatic coagulation and platelet function in those patients are rare. Therefore, this study aims to analyze, whether the bleeding risk in different subgroups of patients with end-stage renal disease can be objectified by extended evaluation of hemostasis using various global assays.

Materials and methods

Patient cohort and study design

Between August 2014 and April 2016 we enrolled a total of 50 participants in our study: 20 patients on hemodialysis (HD), 10 patients on peritoneal dialysis (PD), 10 patients with chronic kidney disease stage G5 (CKD5) as well as 10 healthy controls (HC). All participants showed no signs of acute illness, were non-smokers and had no known hemostatic disorder. Medication was recorded with regard to platelet function inhibitors and anticoagulation therapy.

Standard laboratory values (serum creatinine (sCrea), blood urea nitrogen (BUN), blood count, prothrombin time (PT), activated partial thrombin time (aPTT), international normalized ratio (INR), fibrinogen) and an extended evaluation of hemostasis by means of rotational thromboelastometry (ROTEM) as well as of platelet function by platelet function analyzer (PFA) and multiple electrode aggregometry (Multiplate) were performed. In addition, thrombin generation assays (TGA) and fibrinolytic potential, represented by clot lysis time (CLT) were measured.

The study was performed in accordance with the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. All participants gave written informed consent for analysis of blood values and clinical data. The study was approved by the local ethics committee of the University of Duisburg-Essen (14-5755-BO).

Blood sampling and measurements

Standard laboratory values were gathered from a routine blood drawing after clean venipuncture with additional extraction of a 3 ml trisodiumcitrate monovette and a 2 ml lithium heparin blood gas monovette (Sarstedt, Nümbrecht, Germany) for extended evaluation. In HD patients blood was drawn immediately before a dialysis session with an interval of at least 18 hours since the last treatment.

All laboratory measurements, except rotational thromboelastometry, multiple electrode aggregometry, TGA and fibrinolytic potential were performed by the central laboratory unit of the University Hospital Essen as part of the clinical routine.

The platelet function analyzer-100 (PFA) test measures platelet aggregate formation under high shear rates and with addition of either collagen/epinephrine or collagen/adenosine diphosphate (ADP) as agonists (PFA-Epi and PFA-ADP). Patients with a hematocrit <0.30 were excluded from measurement of PFA.

Thromboelastometry analysis was performed with a ROTEM delta system (Tem Innovations, Munich, Germany) according to the manufacturer's instructions. The tests included EXTEM, INTEM, FIBTEM and APTEM.

As described previously, for EXTEM, 300 μ l citrated whole blood was mixed with 20 μ l tissue factor and 20 μ l CaCl_2 0.2 mol/l. INTEM was performed with 300 μ l citrated whole blood, 20 μ l ellagic acid and 20 μ l CaCl_2 0.2 mol/l. FIBTEM was performed as EXTEM with the addition of cytochalasin D for inhibition of platelets, whereas APTEM was performed with addition of tranexamic acid for inhibition of fibrinolysis [8].

Parameters assessed included clotting time (CT), clot firmness 10 minutes after CT (A10), maximum clot firmness (MCF) and maximum lysis (ML). All tests were performed for at least one hour.

Multiple electrode aggregometry was performed with a Multiplate analyzer (Roche Diagnostics, Mannheim, Germany) according to the manufacturer's instructions. The tests included ADP, ASPI, TRAP and Risto low.

300 μ l 0.9% normal saline solution was mixed with 300 μ l of lithium heparin blood sample and incubated at 37°C for 3 min. ADPtest was performed with addition of 20 μ l of ADP (6.5 μ M). ASPItest was performed with addition of 20 μ l of arachidonic acid (0.5 mM). TRAPtest was performed with addition of 20 μ l of thrombin receptor-activating peptide 6 (32 μ M) and Risto lowtest was performed with addition of 12 μ l ristocetin (0.2 mg/ml). Aggregation was monitored by means of impedance over 6 min and is quantified by the area under the curve (AUC).

All samples were analyzed between 30–90 min post-drawing.

For measurement of TGA and fibrinolytic potential citrated whole blood was centrifuged at 3000 U/min for 15 min within 60 min post-drawing. Plasma was transferred to a different tube and centrifuged again at 3000 U/min for 20 min. The platelet-poor plasma was transferred again and stored at -80°C until measurement.

TGA were performed with the fluorimetric method described by Hemker, Calibrated Automated Thrombography according to the instructions of the manufacturer [9]. As described previously [10], coagulation was activated using a commercial trigger composed of recombinant tissue factor at a concentration of 5 pM and phospholipids at a concentration of 4 μ M (Thrombinoscope BV, Maastricht, The Netherlands) in the presence of a soluble form of thrombomodulin. The lagtime, endogenous thrombin potential (ETP), peak height, and velocity index were derived from the thrombin generation curves by the Thrombinoscope software.

Fibrinolytic potential was assessed as described before [10] using a plasma-based lysis assay. Lysis of a tissue factor-induced clot exogenous tissue plasminogen activator (tPA) was determined by monitoring changes in turbidity during clot formation and subsequent lysis. CLT were derived from the clot-lysis turbidity profiles using in house-generated software. CLT was defined as the time from the midpoint of the clear to maximum turbid transition, representing clot formation, to the midpoint of the maximum turbid to clear transition, representing the lysis of the clot.

Statistical analysis

Data are expressed as mean value \pm standard error of the mean, if not declared otherwise. Comparisons among multiple groups were performed using Kruskal-Wallis test followed by

Dunn’s post-hoc analysis. Additionally, the contribution of different types of renal insufficiency to exceedance of threshold values was evaluated by Fisher’s exact test. A $p < 0.05$ was considered significant.

Results

A total of 50 patients were enrolled in the current study: 20 patients on hemodialysis (HD), 10 patients on peritoneal dialysis (PD), 10 patients with chronic kidney disease stage G5 (CKD5) as well as 10 healthy controls (HC). All participants showed no signs of acute illness and were non-smokers.

Mean age was 45.9 years (minimum 18 years; maximum 77 years) with no significant differences between groups. 50% of study participants were women.

Three patients within the HD group and one patient in the CKD5 group were on treatment with phenprocoumon, while nine patients on HD and 3 patients on PD were treated with aspirin. Patients treated with aspirin were excluded for interpretation of PFA-Epi and ASPItest. Patients treated with phenprocoumon were excluded for interpretation of INR, aPTT and thromboelastometry. No further platelet function inhibitors or anticoagulation therapies were used in the study cohort.

Serum creatinine and blood urea nitrogen

Serum creatinine (sCrea) and blood urea nitrogen (BUN) were within the normal range in all HC. sCrea and BUN were significantly increased in all other groups compared to HC. sCrea was highest in patients with PD (7.46 ± 1.08 mg/dl), while patients with CKD5 showed highest BUN levels (Fig 1).

Blood count

Blood count included measurement of leukocytes, erythrocytes, hemoglobin, hematocrit and platelets.

Leukocytes were within the normal range in all HC. Leukocytes were not significantly different in all other groups compared to HC, but one patient with HD and two patients each with CKD5 and PD showed elevated leukocyte levels.




Fig 1. Creatinine and blood urea nitrogen. Values are given as mean \pm standard error of the mean for each group. Dotted lines mark upper normal range. ** $p < 0.01$ vs. HC; *** $p < 0.001$ vs. HC. HC healthy control, CKD5 patients with chronic kidney disease stage G5, HD patients on hemodialysis, PD patients on peritoneal dialysis.

<https://doi.org/10.1371/journal.pone.0212237.g001>

Erythrocytes and hematocrit were within the normal range in all HC, except one who showed a slight anemia by means of hemoglobin and hematocrit. Erythrocytes, hemoglobin and hematocrit were significantly decreased in all patients with end-stage renal disease compared to HC (each $p < 0.01$). 5 patients with HD and one patient each with CKD5 and PD showed a hemoglobin below 10 g/dl (8.6–9.9 g/dl).

Platelets were within the normal range (180–380 /nl) in all HC. Platelets were not significantly different in all other groups compared to HC, but 12 of 40 patients with end-stage renal disease showed decreased platelets (minimum 99 /nl; median 149 /nl).

International normalized ratio, activated partial thrombin time, prothrombin time, fibrinogen

Spontaneous international normalized ratio (INR) was 0.98 ± 0.01 in the whole cohort (minimum 0.91; maximum 1.48) with no differences between groups.

Activated partial thrombin time was within the normal range (24.4–32.4 sec) in all HC. aPTT was not significantly different in all other groups with 10 patients with end-stage renal disease being slightly out of the normal range (minimum 21.4 sec; maximum 33.4 sec).

Prothrombin time (PT) was prolonged in one patient with PD. No differences between groups were detected.

Fibrinogen was slightly elevated in two HC (269 ± 25 mg/dl). Fibrinogen was significantly increased in patients with PD (Fig 2).

Platelet function analyzer

Platelet function analyzer was only performed in participants with a hematocrit above 30%.

PFA-Epi was prolonged in 20% of HC. No PD patient showed a prolonged PFA-Epi, while 56% of patients with CKD5 and 44% of patients with HD did. There was no statistically significant difference between groups (Fig 3A).




Fig 2. Fibrinogen. Values are given as mean \pm standard error of the mean for each group. Dotted line marks upper normal range. ** $p < 0.01$ vs. HC. HC healthy control, CKD5 patients with chronic kidney disease stage G5, HD patients on hemodialysis, PD patients on peritoneal dialysis.

<https://doi.org/10.1371/journal.pone.0212237.g002>




Fig 3. Platelet function analyzer. The platelet function analyzer (PFA) test measured platelet aggregate formation under high shear rates and with addition of either collagen/epinephrine (A) or collagen/adenosine diphosphate (B) as agonists. Lines indicate mean \pm standard error of the mean for each group. Dotted lines mark upper normal range. * $p < 0.05$ vs. HC; ## $p < 0.01$ vs. PD. HC healthy control, CKD5 patients with chronic kidney disease stage G5, HD patients on hemodialysis, PD patients on peritoneal dialysis.

<https://doi.org/10.1371/journal.pone.0212237.g003>

PFA-ADP was within the normal range in all HC and patients with PD. It was prolonged in 44% of patients with CKD5 and 41% of patients with HD. For patients with CKD5 the difference was statistically significant compared to HC and patients with PD (Fig 3B).

75–80% of CKD5 and HD patients with a prolonged PFA-Epi also showed a prolonged PFA-ADP.

Rotational thromboelastometry

Thromboelastometry analysis performed with a ROTEM included INTEM, EXTEM, FIBTEM and APTEM. Parameters assessed included clotting time (CT), clot firmness 10 minutes after CT (A10), maximum clot firmness (MCF) and maximum lysis (ML).

INTEM reflects activation of coagulation by the intrinsic pathway. No evidence for disturbance of coagulation was detected by any of the parameters in any patient. No differences between groups were measured (Fig 4A).

EXTEM reflects activation of coagulation by the extrinsic pathway. A strongly prolonged clotting time was found in one patient of every group, except for HC (Fig 4B). All other measured parameters were insignificantly changed. No differences between groups were detected.

FIBTEM reflects the plasmatic part of clot firmness. No patient showed reduced clot firmness as detected by FIBTEM. Quite the contrary, maximum clot firmness tended to be increased in patients with end-stage renal disease becoming significant for PD patients (Fig 5). This effect was also shown by an increased A10 ($p < 0.05$ vs. HC).

Hyperfibrinolysis was absent in all patients as measured by comparison of EXTEM and APTEM.

Multiple electrode aggregometry

Multiple electrode aggregometry performed with a Multiplate included ADP, ASPI, TRAP and Risto low (Fig 6).

The ADPtest reflects platelet function following stimulation of the ADP-receptor. It detects inhibition of the P_2Y_{12} receptor [11], which can be pharmacologically blocked by clopidogrel, prasugrel and ticlopidin, as well as inhibition or absence of the platelet integrin $\alpha I\text{Ib}\beta 3$ [12,




Fig 4. Clotting time measured by rotational thromboelastometry. Clotting time in INTEM (A) corresponds to activated partial thrombin time. Clotting time in INTEM was not prolonged in any patient. Clotting time in EXTEM (B) corresponds to prothrombin time. A strongly prolonged clotting time in EXTEM was found in one patient of every group, except HC with all other measured parameters being unchanged. No differences between groups were detected. Lines indicate mean \pm standard error of the mean for each group. Dotted lines indicate normal range. *HC* healthy control, *CKD5* patients with chronic kidney disease stage G5, *HD* patients on hemodialysis, *PD* patients on peritoneal dialysis.

<https://doi.org/10.1371/journal.pone.0212237.g004>

13]. A reduced area under the curve (AUC) was detected in none of the HC, while 20% of CKD5, 25% of HD and 40% of PD patients showed reduced AUCs. Differences between groups were not statistically significant.

The ASPItest reflects platelet function following stimulation with arachidonic acid. It detects inhibition of the platelet cyclooxygenase [14] as well as inhibition or absence of the platelet integrin α IIB β 3 [12, 15]. A reduced AUC was detected in 20% of HC, while 30% of CKD5, 45% of HD and 57% of PD patients showed reduced AUCs. Differences between groups were not statistically significant.




Fig 5. Maximum clot firmness measured by rotational thromboelastometry (FIBTEM). FIBTEM reflects the plasmatic part of clot firmness. Clot firmness tended to be increased in patients with end-stage renal disease becoming significant for PD patients. * $p < 0.05$ vs. HC. Lines indicate mean \pm standard error of the mean for each group. Dotted lines indicate normal range. *HC* healthy control, *CKD5* patients with chronic kidney disease stage G5, *HD* patients on hemodialysis, *PD* patients on peritoneal dialysis.

<https://doi.org/10.1371/journal.pone.0212237.g005>




Fig 6. Results of multiple electrode aggregometry. ADPtest (A) reflects function of the P_2Y_{12} and GpIIb/IIIa receptor. ASPITest (B) reflects function of the platelet cyclooxygenase and the GpIIb/IIIa receptor. TRAPtest (C) reflects function of the protease-activated receptor 1 and the GpIIb/IIIa receptor. RISTOlowTest (D) reflects function of von Willebrand Factor. No significant differences between groups were detected. Lines indicate mean \pm standard error of the mean for each group. Dotted lines indicate normal range. *HC* healthy control, *CKD5* patients with chronic kidney disease stage G5, *HD* patients on hemodialysis, *PD* patients on peritoneal dialysis.

<https://doi.org/10.1371/journal.pone.0212237.g006>

The TRAPtest reflects platelet function following stimulation with thrombin receptor activating peptide-6 (TRAP-6). It detects function of the protease-activated receptor 1 (PAR-1) and is reduced in case of inhibition or absence of the platelet integrin $\alpha IIb\beta 3$ [12, 15]. A reduced AUC was detected in 20% of HC, while 10% of CKD5 and HD, as well as 20% of PD patients showed reduced AUCs. Differences between groups were not statistically significant.

The RISTOlowtest reflects platelet function following induction of agglutination by ristocetin. A strong agglutination response is not expected in the RISTOlowtest, while enhanced aggregation tendency of von Willebrand Factor might result in a higher AUC. An increased AUC was detected in 40% of HC, while 30% of CKD5, 40% of PD and 75% of HD patients ($p = 0.06$) showed increased AUCs. Differences between groups were not statistically significant.

There was no correlation between the results of the multiple electrode aggregometry and the PFA.




Fig 7. Results of thrombin generation assays. Data are given as medians with interquartile ranges. * $p < 0.05$ and *** $p < 0.001$ vs. HC. HC healthy control, CKD5 patients with chronic kidney disease stage G5, HD patients on hemodialysis, PD patients on peritoneal dialysis.

<https://doi.org/10.1371/journal.pone.0212237.g007>

Thrombin generation assays

Results of the TGA are shown in Fig 7.

The TGA reflects the capacity of plasma to generate thrombin after in vitro activation of coagulation.

The lagtime was longer in patients with end-stage kidney disease compared to healthy controls. Peak thrombin, ETP, and velocity index were lower in patients with hemodialysis compared to healthy controls.

Fibrinolytic potential

CLT representing fibrinolytic potential was prolonged in patients with HD and PD compared to healthy controls (both $p < 0.001$) indicating a hypofibrinolytic state (Fig 8).

Discussion

Results of the present study indicate a clopidogrel-like platelet dysfunction in patients with CKD5 and patients with HD treatment becoming concrete in a prolonged PFA-ADP test in patients with CKD5 compared to HC. Multiple electrode aggregometry confirmed a complex platelet defect, although ristocetin-induced agglutination was enhanced in a proportion of




Fig 8. Clot lysis time. Data are given as medians with interquartile ranges. *** $p < 0.001$ vs. HC. HC healthy control, CKD5 patients with chronic kidney disease stage G5, HD patients on hemodialysis, PD patients on peritoneal dialysis.

<https://doi.org/10.1371/journal.pone.0212237.g008>

patients. Besides platelet dysfunction, thrombin generating potential seems to be decreased in all patients becoming significant for patients on HD.

On the contrary, clot lysis time which is highly significantly prolonged in patients with HD and PD indicates a hypofibrinolytic state. In addition, patients on PD have elevated fibrinogen levels and enhanced whole blood clot formation.

An increased bleeding risk has been described for patients with end-stage renal disease. This bleeding risk was besides anemia and drugs attributed to insufficient platelet function and disturbed interaction between platelets and the vessel walls [2]. On the other hand, end-stage renal disease is also associated with an increased risk for venous thromboembolism [16] and dialysis patients shown an increased risk of pulmonary embolism compared to general population [17] which might even be worse in HD patients than in patients treated by PD [18].

Uremic toxins influence platelet function [19], however BUN levels as a marker for uremic toxins were not linked to any hemostatic alteration in our study being in line with Remuzzi et al. who could not show a correlation between bleeding time and uremic metabolites [20]. Anemia has been described as an important factor for the development of bleeding disorders as hemoglobin is a scavenger of NO and erythrocyte flow leads to localization of platelets along the endothelium encouraging platelet-vessel wall interaction [21, 22]. However, current KDIGO guidelines recommend to only use erythropoietin-stimulating agents for treatment of renal anemia in patients with a hemoglobin ≤ 10 g/dl as a further increase in hemoglobin has shown to provide more harm than benefit [23]. Seven patients showed a hemoglobin below 10 g/dl with none of those having a short-term history of acute bleeding or being symptomatic.

Increased levels of fibrinogen in patients with chronic kidney disease as part of the pro-inflammatory state [24, 25] have been described before. Elevated fibrinogen levels in patients treated with PD [26] might be due long-term peritoneal exposure to especially glucose-based dialysate creating an pro-inflammatory environment exceeding that of HD patients. Increased fibrinogen levels in PD patients were reflect by FIBTEM results of rotational

thromboelastometry and may have contributed to a hypofibrinolytic state using a test clearly related to thrombotic disease [27]. No patient in our cohort had switched from HD to PD due to vessel access problems. A more prothrombotic state of PD patients compared to HD patients has been described before [26].

PFA-Epi was prolonged in 56% of patients with CKD5 and 44% of patients with HD, PFA-ADP was prolonged in 44% of patients with CKD5 and 41% of patients with HD. Although results were only significant compared to HC for PFA-ADP in CKD5 patients tests indicate a platelet disorder. As platelets are involved in primary hemostasis this might cause problems in case of acute (traumatic) bleedings from cannulations sites, the gastrointestinal tract or following (kidney) biopsies or surgery. The differences between PFA and multiple electrode aggregometry, which showed a tendency for a higher AUC in RISTOlow indicating an enhanced aggregation tendency at least for HD patients, are not per se surprising as PFA measures adhesion and aggregation under flow, whereas multiple electrode aggregometry is a test of aggregation only. Therefore, the results are in line with Zwaginga et al., who found no platelet defect in suspension aggregation, but platelet defects in experimental flow models with uremic blood [28]. In addition, it was reported previously that high levels of the platelet adhesive protein von Willebrand factor compensate for the platelet function defect in patients with renal disease [29], which are in line with our current results on enhanced platelet agglutination by ristocetin, which is dependent on von Willebrand factor. The differences between HD and PD on platelets are profound, with more ex vivo platelet activation (and thrombocytopenia) and dilution induced in the HD circuit. Every available platelet test measures a different aspect of platelet function, and correlation between tests is very poor.

Although thrombin generating potential was decreased to some degree in all patients with end-stage kidney disease, which was shown before [10], a hypercoagulable state was found especially for PD patients going along with a generally increased risk for venous thromboembolism. Our results are in line with Nieuwenhuijs-Moeke et al. who showed an hypercoagulable state in preemptively and non-preemptively transplanted patients tested during surgery compared to living kidney donors [10]. Detection of platelet function disorders stays rather vague and inhomogeneous, but explains bleeding complications following interventions. The general concept that renal disease patients are not only bleeders is supported by both clinical and laboratory evidence.

There are some limitations to our study. Due to limited cohort size the impact of the underlying diseases on hemostasis could not be addressed. None of the patients included had been diagnosed with a coagulation disorder. Medication was only considered with respect to inhibitors of platelet aggregation and systemic anticoagulation. None of the patients included received antibiotics.

A power calculation was not performed as we did not have data on the variation of the various hemostatic tests performed in the particular patient groups. As the number of measurements was limited, we did not include tests depicting interaction of platelets and vessel wall such as von Willebrand factor.

Conclusions

In conclusion, our results indicate that patients with end-stage renal disease have clear hypercoagulable features, which is not in line with the clinical concept of patients with end-stage renal disease being bleeders. However, end-stage renal disease seems to be associated with platelet dysfunction which disables primary hemostasis in cases of acute bleeding. At this time, it is impossible to conceive the global hemostatic state of an individual patient in a feasible and accepted test model.

Supporting information

S1 File. Raw data. Detailed results of all experiments performed. (XML)

Acknowledgments

The authors thank Angelika Jonait, Simone Hempel and Tanja Hinkeldein for their excellent assistance. The authors thank Jelle Adelmeijer for expert technical assistance.

Author Contributions

Conceptualization: Anja Gäckler, Andreas Kribben, Fuat H. Saner.

Data curation: Anja Gäckler, Fuat H. Saner.

Formal analysis: Anja Gäckler, Ton Lisman, Fuat H. Saner.

Investigation: Anja Gäckler, Hana Rohn, Ton Lisman, Fuat H. Saner.

Methodology: Ton Lisman.

Resources: Fuat H. Saner.

Visualization: Anja Gäckler.

Writing – original draft: Anja Gäckler, Fuat H. Saner.

Writing – review & editing: Anja Gäckler, Hana Rohn, Ton Lisman, Tamas Benkö, Oliver Witzke, Andreas Kribben, Fuat H. Saner.

References

1. Pavord S, Myers B. Bleeding and thrombotic complications of kidney disease. *Blood Reviews*. 2011; 25:271–8. <https://doi.org/10.1016/j.blre.2011.07.001> PMID: 21872374
2. Lutz J, Menke J, Sollinger D, Schinzel H, Thürmel K. Haemostasis in chronic kidney disease. *Nephrol Dial Transplant*. 2014; 29:29–40. <https://doi.org/10.1093/ndt/gft209> PMID: 24132242
3. Tanhehco Y, Berns J. Red blood cell transfusion risks in patients with end-stage renal disease. *Semin Dial*. 2012; 25(5):539–44. <https://doi.org/10.1111/j.1525-139X.2012.01089.x> PMID: 22686519
4. Acedillo R, Shah M, Devereaux P, Li L, Iansavichus A, Walsh M, et al. The risk of perioperative bleeding in patients with chronic kidney disease. *Ann Surg*. 2013; 258:901–13. <https://doi.org/10.1097/SLA.000000000000244> PMID: 24169162
5. Mohapatra A, Valson A, Gopal B, Singh S, Nair S, Viswabandya A, et al. Hemostatic abnormalities in severe renal failure: do they bark or bite? *Indian J Nephrol*. 2018; 28(2):135–42. https://doi.org/10.4103/ijn.IJN_104_17 PMID: 29861564
6. Lu H, Liao K. Increased risk of deep vein thrombosis in end-stage renal disease. *BMC Nephrol*. 2018; 19(1):204. <https://doi.org/10.1186/s12882-018-0989-z> PMID: 30115029
7. Cheung K, Zakai N, Folsom A, Kurella Tamura M, Peralta C, Judd S, et al. Measures of kidney disease and the risk of venous thromboembolism in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study. *Am J Kidney Dis*. 2017; 70(2):182–90. <https://doi.org/10.1053/j.ajkd.2016.10.039> PMID: 28126238
8. Bedreli S, Sowa J, Malek S, Blomeyer S, Katsounas A, Gerken G, et al. Rotational thromboelastometry can detect factor XIII deficiency and bleeding diathesis in patients with cirrhosis. *Liver Int*. 2017; 37(4):562–8. <https://doi.org/10.1111/liv.13254> PMID: 27634287
9. Hemker H, Giesen P, AlDieri R, Regnault V, de Smed E, Wagenvoort R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. *Pathophysiol Haemost Thromb*. 2002; 32(5–6):249–53. <https://doi.org/10.1159/000073575> PMID: 13679651
10. Nieuwenhuijs-Moeke G, van den Berg T, Bakker S, van den Heuvel M, Struys M, Lisman T, et al. Pre-emptively and non-preemptively transplanted patients show a comparable hypercoagulable state prior to

- kidney transplantation compared to living kidney donors. *PLoS One*. 2018; 13(7):e0200537. <https://doi.org/10.1371/journal.pone.0200537> PMID: 30011293
11. Sibbing D, Braun S, Jawansky S, Vogt W, Mehilli J, Schömig A, et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. *Thromb Haemost*. 2008; 99(1):121–6. <https://doi.org/10.1160/TH07-07-0478> PMID: 18217143
 12. Halimeh S, Angelis G, Sander A, Edelbusch C, Rott H, Thedieck S, et al. Multiplate whole blood impedance point of care aggregometry: preliminary reference values in healthy infants, children and adolescents. *Klin Padiatr*. 2010; 222(3):158–63. <https://doi.org/10.1055/s-0030-1249081> PMID: 20514620
 13. Awidi A, Maqablah A, Dweik M, Bsoul N, Abu-Khader A. Comparison of platelet aggregation using light transmission and multiple electrode aggregometry in Glanzmann thrombasthenia. *Platelets*. 2009; 20(5):297–301. <https://doi.org/10.1080/09537100903006246> PMID: 19548178
 14. Jámbor C, Weber C, Gerhardt K, Dietrich W, Spannagl M, Heindl B, et al. Whole blood multiple electrode aggregometry is a reliable point-of-care test of aspirin-induced platelet dysfunction. *Anesth Analg*. 2009; 109(1):25–31. <https://doi.org/10.1213/ane.0b013e3181a27d10> PMID: 19439684
 15. Desch S, Siegemund A, Scholz U, Adam N, Eitel I, de Waha S, et al. Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction. *Clin Res Cardiol*. 2012; 101(2):117–24. <https://doi.org/10.1007/s00392-011-0372-6> PMID: 22015616
 16. Ocak G, Lijfering W, Verduijn M, Dekker F, Rosendaal F, Cannegieter S, et al. Risk of venous thrombosis in patients with chronic kidney disease: identification of high-risk groups. *J Thromb Haemost*. 2013; 11(4):627–33. <https://doi.org/10.1111/jth.12141> PMID: 23433091
 17. Ocak G, van Stralen K, Rosendaal F, Verduijn M, Ravani P, Palsson R, et al. Mortality due to pulmonary embolism, myocardial infarction, and stroke among incident dialysis patients. *J Thromb Haemost*. 2012; 10(12):2484–93. <https://doi.org/10.1111/j.1538-7836.2012.04921.x> PMID: 22970891
 18. Wang I, Shen T, Muo C, Yen T, Sung F. Risk of pulmonary embolism in patients with end-stage renal disease receiving long-term dialysis. *Nephrol Dial Transplant*. 2017; 32(8):1386–93. <https://doi.org/10.1093/ndt/gfw272> PMID: 27448674
 19. Horowitz H. Uremic toxins and platelet function. *Arch Intern Med*. 1970; 126:823–926. PMID: 5475705
 20. Remuzzi G, Livio M, Marchiaro G, Mecca G, de Gaetano G. Bleeding in renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. *Nephron*. 1978; 22(4–6):347–53. <https://doi.org/10.1159/000181474> PMID: 740096
 21. Gaarder A, Jonsen J, Laland S, Hellem A, Owren P. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. *Nature*. 1961; 192:531–2. PMID: 13896038
 22. Martin W, Villani G, Jothianandan D, Furchgott R. Blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation of rabbit aorta by certain ferrous hemoproteins. *J Pharmacol Exp Ther*. 1985; 233(3):679–85. PMID: 2861277
 23. Group KDIGOKAW. KDIGO clinical practice guideline for anemia in chronic kidney disease. *Kidney Int, Suppl*. 2012; 2:279–335.
 24. Shlipak M, Fried L, Crump C, Bleyer A, Manolio T, Tracy R, et al. Elevations of inflammatory and pro-coagulant biomarkers in elderly persons with renal insufficiency. *Circulation*. 2003; 107(1):87–92. PMID: 12515748
 25. de la Serna G. Fibrinogen: a new major risk factor for cardiovascular disease. A review of the literature. *J Fam Pract*. 1994; 39:468–77. PMID: 7964545
 26. Brophy D, Carl D, Mohammed B, Song J, Martin E, Bostic J, et al. Differences in coagulation between hemodialysis and peritoneal dialysis. *Perit Dial Int*. 2014; 34(1):33–40. <https://doi.org/10.3747/pdi.2013.00036> PMID: 24293664
 27. Lisman T. Decreased plasma fibrinolytic potential as a risk for venous and arterial thrombosis. *Semin Thromb Hemost*. 2017; 43(2):178–84. <https://doi.org/10.1055/s-0036-1585081> PMID: 27472427
 28. Zwavinga J, Ijsseldijk M, de Groot P, Vos J, de Bos Kuil R, Sixma J. Defects in platelet adhesion and aggregate formation in uremic bleeding disorder can be attributed to factors in plasma. *Arterioscler Thromb*. 1991; 11(3):733–44. PMID: 2029508
 29. Zwavinga J, Ijsseldijk M, Beeser-Visser N, de Groot P, Vos J, Sixma J. High von Willebrand factor concentration compensates a relative adhesion defect in uremic blood. *Blood*. 1990; 75(7):1498–508. PMID: 2156581